Toleranzia signs agreement with British nanomedicine company

14 November - 2016

Toleranzia AB (“Toleranzia”) has entered into an agreement with Tecrea Ltd. (“Tecrea”), a London-based company with a patented technology in nanomedicine, with attractive potential applications in the field of tolerance therapies. The agreement gives Toleranzia the opportunity to exclusively use the technology for the treatment of myasthenia gravis, the company’s main indication. For Tecrea, the collaboration, in an exciting new therapy area, contributes to a growing portfolio of partnerships.

Nanomedicine brings new opportunities
Tecrea’s technology is based on the incorporation of drugs into so-called nanoparticles. The nanoparticles can be tailored with respect to size, charge, and shape for different applications. For Toleranzia’s tolerogens, this new way of formulating can bring characteristics such as increased stability and protection against degradation, as well as efficient cell targeting and cellular uptake. The use of tolerogens in nanoparticle formulation may also result in that the amount of protein needed for an effective treatment can be significantly reduced. A great advantage of Tecrea’s technology is that the materials used to build the nanoparticles are well known, the production is easy and their safety for human use is well documented for a number of applications.

The way forward
The company, in collaboration with Tecrea, intends to produce Nanocin™ nanoparticles incorporating Toleranzia’s tolerogens and evaluate their properties in animal models of myasthenia gravis.

CEO Charlotte Fribert comments
“Tecrea is a well-established nanomedicine company with major pharmaceutical companies and universities as partners, a qua­li­ty that provides the best possible starting point for a collaboration. The agreement with Tecrea opens new avenues for Toleranzia to further improve the properties of the company’s tolerogens. We look forward to starting the collaboration.”

Liam Good, CEO of Tecrea, comments
“Tecrea are delighted to be working in partnership with Toleranzia. The company has a robust drug development platform and technical expertise, which is an excellent basis for cooperation. This agreement with Tolerenzia adds to our growing list of high-profile partnerships in a diverse range of disease areas. We look forward to a productive working relationship with Toleranzia.”

For further information, please contact:
Charlotte Fribert – CEO
Phone: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com

This information is information that Toleranzia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, November 14, 2016.

About Toleranzia AB
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.

About Tecrea Ltd.
Tecrea Ltd., founded in 2012, is a privately owned company, registered in the United Kingdom. Company nanoparticle platform Nanocin ™ provides an improved formulation of nucleic acids, proteins, peptides and small molecules for clinical application. The goal is to offer world-leading cell and tissue specific delivery technology for research and development of pharmaceutical applications. From the base in London, driven collaborations with industrial, academic and government partners locally and globally. Read more at: www.tecrea.co.uk.